<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Int Braz J Urol</journal-id><journal-id journal-id-type="iso-abbrev">Int Braz J Urol</journal-id><journal-id journal-id-type="publisher-id">ibju</journal-id><journal-title-group><journal-title>International Brazilian Journal of Urology : official journal of the Brazilian Society of Urology</journal-title></journal-title-group><issn pub-type="ppub">1677-5538</issn><issn pub-type="epub">1677-6119</issn><publisher><publisher-name>Sociedade Brasileira de Urologia</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">28379666</article-id><article-id pub-id-type="pmc">5557438</article-id><article-id pub-id-type="publisher-id">S1677-5538.IBJU.2016.0316</article-id><article-id pub-id-type="doi">10.1590/S1677-5538.IBJU.2016.0316</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>SCUBE1: a promising biomarker in renal cell cancer</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Karag&#x000fc;zel</surname><given-names>Ersagun</given-names></name><xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Mente&#x0015f;e</surname><given-names>Ahmet</given-names></name><xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>O.Kazaz</surname><given-names>&#x00130;lke</given-names></name><xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Demir</surname><given-names>Selim</given-names></name><xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>&#x000d6;rem</surname><given-names>Asim</given-names></name><xref ref-type="aff" rid="aff4">
<sup>4</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Okatan</surname><given-names>Ali Ertan</given-names></name><xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Altay</surname><given-names>Diler Us</given-names></name><xref ref-type="aff" rid="aff5">
<sup>5</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Yaman</surname><given-names>Serap &#x000d6;zer</given-names></name><xref ref-type="aff" rid="aff4">
<sup>4</sup>
</xref></contrib></contrib-group><aff id="aff1">
<label>1</label>Department of Urology, Karadeniz Technical University, Faculty of Medicine, Trabzon, Turkey;</aff><aff id="aff2">
<label>2</label> Program of Medical Laboratory Techniques, Karadeniz Technical University, Vocational School of Health Sciences, Trabzon, Turkey;</aff><aff id="aff3">
<label>3</label>Department of Nutrition and Dietetics, Karadeniz Technical University, Faculty of Health Sciences, Trabzon, Turkey;</aff><aff id="aff4">
<label>4</label>Department of Medical Biochemistry, Karadeniz Technical University, Faculty of Medicine, Trabzon, Turkey;</aff><aff id="aff5">
<label>5</label>Department of Chemistry and Chemical Processing Technology, Ordu University, Ulubey Vocational School, Ordu, Turkey</aff><author-notes><corresp id="c01"><bold>Correspondence address:</bold> Ersagun Karag&#x000fc;zel, MD. Department of Urology. Karadeniz Technical University, School of Medicine. 61080, Trabzon, Turkey. Fax: + 90 462 325-0518. E-mail: <email>ersagunkaraguzel@gmail.com</email></corresp><fn fn-type="COI-statement"><p>
<bold>CONFLICT OF INTEREST</bold>
</p><p>None declared.</p></fn></author-notes><pub-date pub-type="epub-ppub"><season>Jul-Aug</season><year>2017</year></pub-date><!--Fake ppub date generated by PMC from publisher
							pub-date/@pub-type='epub-ppub' --><pub-date pub-type="ppub"><season>Jul-Aug</season><year>2017</year></pub-date><volume>43</volume><issue>4</issue><fpage>638</fpage><lpage>643</lpage><history><date date-type="received"><day>02</day><month>6</month><year>2016</year></date><date date-type="rev-recd"><day>04</day><month>1</month><year>2017</year></date><date date-type="accepted"><day>22</day><month>3</month><year>2017</year></date></history><permissions><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p> This is an Open Access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. </license-p></license></permissions><abstract><title>ABSTRACT</title><sec><title>Purpose</title><p> To investigate the efficacy of signal peptide-CUB-EGF domain-containing protein 1 (SCUBE-1) as a novel biomarker of renal tumors.</p></sec><sec><title>Materials and Methods</title><p> 48 individuals were included in the study. The patient group (Group-1) consisted of 23 subjects diagnosed with renal tumor, and the control group (Group-2) of 25 healthy individuals. Patients diagnosed with renal tumor received surgical treatment consisting of radical or partial nephrectomy. Blood specimens were collected following overnight fasting. Signal peptide-CUB-EGF domain-containing protein 1 (SCUBE-1), soluble urokinase plasminogen activator receptor (suPAR) and carbonic anhydrase IX (CA IX) levels were measured from plasma samples. Patients in groups 1 and 2 were compared in terms of these biochemical parameters.</p></sec><sec><title>Results</title><p> The 23-member renal tumor group was made up of 17 (73.91%) male and 6 (26.08%) female patients with a mean age of 58.5&#x000b1;15.7 years (range 25 to 80). The 24-member healthy control group was made up of 16 (64%) male and 9 (36%) female subjects with a mean age of 52.4&#x000b1;9.12 years (range 40 to 67). Analysis revealed significant elevation in SCUBE-1 levels in the renal tumor group (p=0.005). No significant differences were detected between the groups with regard to CA IX or suPAR measurements (p=0.062 vs. p=0.176).</p></sec><sec><title>Conclusions</title><p> SCUBE-1 appears to represent a promising biomarker in the diagnosis and follow-up of patients with renal tumor.</p></sec></abstract><kwd-group><kwd>Carcinoma, Renal Cell</kwd><kwd>Biomarkers</kwd></kwd-group><counts><fig-count count="0"/><table-count count="3"/><equation-count count="0"/><ref-count count="28"/><page-count count="6"/></counts></article-meta></front><body><sec sec-type="intro"><title>INTRODUCTION</title><p>Renal cell carcinoma represents 2-3% of all adult malignancy neoplasms and is the most lethal urological cancer (<xref rid="B1" ref-type="bibr">1</xref>). Clear cell renal cell carcinoma (CCRCC) constitutes approximately 80% of renal cell carcinomas and follows a more aggressive course than papillary and chromophobe carcinoma, other pathological subtypes. Metastasis is present at diagnosis in approximate 1/3 patients, and there is a 30-40% risk of metastasis developing after surgery in subjects with localized disease at time of diagnosis (<xref rid="B2" ref-type="bibr">2</xref>). Radical or partial nephrectomy is the current gold standard in the treatment of localized disease.</p><p>Clinical, anatomical and histopathological criteria are used to determine prognosis of renal cancer. However, research aimed at identifying a biomarker that can be used in diagnosis, monitoring and determining tumors with a high risk of recurrence and that can show the need for early adjuvant and advanced treatment in metastatic patients is still ongoing.</p><p>Transmembrane carbonic anhydrase IX (CAIX) is one component of the carbonic anhydrase family. It is an efficient catalyst of the reversible hydration of carbon dioxide into bicarbonate and a proton. This permits tumor cells to preserve a neutral pH in the presence of an acidic microenvironment. Expression of CAIX does not occur in healthy kidney tissue. However, it does occur in the majority of CCRCCs. This occurs by way of HIF-1a overexpression caused by hypoxia and inactivation of the von Hippel-Landau gene (<xref rid="B3" ref-type="bibr">3</xref>). Some studies have described CA IX as a prognostic marker in patients with metastatic clear-cell renal cell carcinoma (mccRCC) (<xref rid="B4" ref-type="bibr">4</xref>). CAIX, one of the most studied biomarker in CCRCC, is considered promising.</p><p>Soluble urokinase plasminogen activator receptor (suPAR) is a glycosylphosphatidylinositol (GPI) membrane protein that binds to urokinase-type plasminogen activator receptor (uPAR) in soluble form (<xref rid="B5" ref-type="bibr">5</xref>) suPAR is produced by various types of cells, such as vascular endothelial cells, neutrophils and monocytes, and is thought to be associated with chronic inflammatory conditions (<xref rid="B6" ref-type="bibr">6</xref>). Studies have shown that suPAR is correlated with poor prognosis in some types of cancer (<xref rid="B7" ref-type="bibr">7</xref>, <xref rid="B8" ref-type="bibr">8</xref>).</p><p>Signal peptide-CUB-EGF domain-containing protein 1 (SCUBE-1) is a cell surface glycoprotein. This novel biochemical marker is expressed and secreted in early embryogenesis and is present in platelets and endothelial cells (<xref rid="B9" ref-type="bibr">9</xref>). The SCUBE gene family contains three different isoforms, including SCUBE-1 (SCUBE 1-3) (<xref rid="B10" ref-type="bibr">10</xref>). SCUBE-1, a cell surface protein, has been investigated in various types of cancer and non-cancer diseases.</p><p>Based on the objective of developing a biomarker capable of use in renal tumors, we investigated SCUBE-1, a marker that has not previously been studied in patients with renal tumor. We compared SCUBE-1, a potentially novel marker, with CA IX and suPAR, previously investigated markers in renal tumors.</p></sec><sec sec-type="materials|methods"><title>MATERIAL AND METHODS</title><sec><title>Study population</title><p>Forty-eight individuals were included in the study, 23 patients diagnosed with renal tumor (Group-1) and a control group of 25 healthy subjects (Group-2). All members of both groups provided informed consent. The Karadeniz Technical University Medical Faculty Ethical Committee approved the study. All of the patients were evaluated clinically and they were also previously biochemical and radiologically investigated. Surgical treatment in the form of radical or partial nephrectomy was performed in all cases of diagnosed renal tumor.</p></sec><sec><title>Blood samples</title><p>Blood samples were collected from patients following overnight fasting. These were taken from the peripheral vein and stored at 4&#x000ba;C. Plasma specimens were obtained by centrifuging the blood samples at 3000rpm for 10 min. Plasma specimens were then stored at -80&#x000ba;C until biochemical analysis.</p></sec><sec><title>Biochemical measurements</title><sec><title>Measurement of signal peptide-CUB-EGF domain-containing protein 1 (SCUBE-1) levels.</title><p>Levels of SCUBE-1 were determined using an enzyme-linked immunosorbent assay kit (Cusabio Biotech Co., Catalog No. CSB-E15005h, P.R. China) in line with the manufacturer&#x02019;s instructions. The absorbance of samples was measured at 450nm using a VersaMax tunable microplate reader (designed by Molecular Devices in California, USA). The results were expressed as ng/mL. The minimum detectable level of human SCUBE-1 is generally lower than 0.16ng/mL.</p></sec><sec><title>Measurement of soluble urokinase plasminogen activator receptor (suPAR) levels.</title><p>Levels of suPAR were determined using an enzyme-linked immunosorbent assay kit (ViroGates A/S., Denmark) following the manufacturer&#x02019;s protocols. The absorbance of samples was measured at 450nm using a VersaMax tunable microplate reader (designed by Molecular Devices in California, USA). The results were expressed as ng/mL. The estimated detection limit was 0.1ng/mL.</p></sec><sec><title>Measurement of carbonic anhydrase IX (CA IX) levels.</title><p>Serum levels of human CA IX were determined using an enzyme-linked immunosorbent assay kit (R&#x00026;D systems, Catalog No. DCA 900, P.R. China) in line with the manufacturer&#x02019;s protocols. The absorbance of samples was measured at 450nm using a VersaMax tunable microplate reader (Designed by Molecular Devices in California, USA). The results were expressed as pg/mL. The minimum detectable dose of human CA IX is generally lower than 2.28pg/mL.</p></sec></sec></sec><sec><title>Statistical analysis</title><p>Statistical analyses were performed using computer software (SPSS version 13.0 software, Chicago, Illinois, USA). Data were expressed as mean&#x000b1;standard deviation. The Mann-Whitney U test and t-test were used for statistical analyses. Spearman correlation analysis was used to determine the correlation between biochemical parameters in the groups. Statistical signi&#x0fb01;cance was set at p&#x0003c;0.05.</p></sec><sec sec-type="results"><title>RESULTS</title><p>Forty-eight patients were enrolled in the study. The renal tumor group consisted of 23 patients, 17 (73.91%) of whom were male and 6 (26.08%) female, with a mean age of 58.5&#x000b1;15.7 (range 25 to 80). The healthy control group consisted of 24 subjects, 16 (64%) male and 9 (36%) female, with a mean age of 52.4&#x000b1;9.12 (range 40 to 67). Tumors were removed by the methods of radical nephrectomy and partial nephrectomy (nephron sparing surgery) in 18 patients (78.3%) and 5 patients (21.7%), respectively. The pathological distribution of the tumors (pathological type, Fuhrman&#x02019;s nuclear grade, pathological stage) in patients is shown in <xref ref-type="table" rid="t1">Table-1</xref>.</p><p>
<table-wrap id="t1" orientation="portrait" position="float"><label>Table 1</label><caption><title>The pathological distribution of the tumors in patients.</title></caption><table frame="hsides" rules="groups"><colgroup width="50%" span="1"><col span="1"/><col span="1"/></colgroup><thead><tr><th align="left" style="font-weight:normal" rowspan="1" colspan="1">&#x000a0;</th><th style="font-weight:normal" rowspan="1" colspan="1">n (%)</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">
<bold>Pathological type</bold>
</td><td rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td rowspan="1" colspan="1">Clear Cell RCC</td><td align="center" rowspan="1" colspan="1">17 (73.9)</td></tr><tr><td rowspan="1" colspan="1">Papillary RCC</td><td align="center" rowspan="1" colspan="1">4 (17.3)</td></tr><tr><td rowspan="1" colspan="1">Chromophobe RCC</td><td align="center" rowspan="1" colspan="1">2 (8.6)</td></tr><tr><td rowspan="1" colspan="1">
<bold>Fuhrman&#x02019;s nuclear grade</bold>
</td><td rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td rowspan="1" colspan="1">Grade 1</td><td align="center" rowspan="1" colspan="1">7 (30.4)</td></tr><tr><td rowspan="1" colspan="1">Grade 2</td><td align="center" rowspan="1" colspan="1">11 (47.8)</td></tr><tr><td rowspan="1" colspan="1">Grade 3</td><td align="center" rowspan="1" colspan="1">3 (13.0)</td></tr><tr><td rowspan="1" colspan="1">Grade 4</td><td align="center" rowspan="1" colspan="1">2 (8.6)</td></tr><tr><td rowspan="1" colspan="1">
<bold>Pathological stage</bold>
</td><td rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td rowspan="1" colspan="1">pT1a</td><td align="center" rowspan="1" colspan="1">10 (43.4)</td></tr><tr><td rowspan="1" colspan="1">pT1b</td><td align="center" rowspan="1" colspan="1">7 (30.4)</td></tr><tr><td rowspan="1" colspan="1">pT2a</td><td align="center" rowspan="1" colspan="1">3 (13.0)</td></tr><tr><td rowspan="1" colspan="1">pT2b</td><td align="center" rowspan="1" colspan="1">2 (8.6)</td></tr><tr><td rowspan="1" colspan="1">pT3a</td><td align="center" rowspan="1" colspan="1">1 (4.3)</td></tr></tbody></table><table-wrap-foot><fn id="TFN1"><p>
<bold>RCC =</bold> Renal cell cancer</p></fn></table-wrap-foot></table-wrap>
</p><p>Distribution of biochemical parameters in the two groups is shown in <xref ref-type="table" rid="t2">Table-2</xref>. Comparison of groups 1 and 2 revealed significantly elevated SCUBE-1 levels in the patients with renal tumor (p=0.005). No significant differences were observed between groups 1 and 2 in terms of CA IX or suPAR values (p=0.062 vs. p=0.176). There were also no significant differences between groups in terms of pathological type and stage and the Fuhrman&#x02019;s grade (p&#x0003e;0.05).</p><p>
<table-wrap id="t2" orientation="portrait" position="float"><label>Table 2</label><caption><title>Comparison of biochemical parameters in the patient and control groups.</title></caption><table frame="hsides" rules="groups"><colgroup width="25%" span="1"><col span="1"/><col span="1"/><col span="1"/><col span="1"/></colgroup><thead><tr><th align="left" style="font-weight:normal" rowspan="1" colspan="1">Biochemical parameters</th><th style="font-weight:normal" rowspan="1" colspan="1">Group 1 Patient group</th><th style="font-weight:normal" rowspan="1" colspan="1">Group 2 Control group</th><th style="font-weight:normal" rowspan="1" colspan="1">P value (p&#x0003c;0.05)</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">SCUBE1 (ng/mL)</td><td align="center" rowspan="1" colspan="1">14.80 &#x000b1; 3.17</td><td align="center" rowspan="1" colspan="1">8.60 &#x000b1; 5.22</td><td align="center" rowspan="1" colspan="1">0.005</td></tr><tr><td rowspan="1" colspan="1">CAIX (pg/mL)</td><td align="center" rowspan="1" colspan="1">59.06 &#x000b1; 61.38</td><td align="center" rowspan="1" colspan="1">43.39 &#x000b1; 61.73</td><td align="center" rowspan="1" colspan="1">0.176</td></tr><tr><td rowspan="1" colspan="1">suPAR (ng/mL)</td><td align="center" rowspan="1" colspan="1">7.54 &#x000b1; 6.31</td><td align="center" rowspan="1" colspan="1">4.29 &#x000b1; 5.23</td><td align="center" rowspan="1" colspan="1">0.062</td></tr></tbody></table><table-wrap-foot><fn id="TFN2"><p>
<bold>SCUBE-1 =</bold> Signal peptide-CUB-EGF domain-containing protein 1; <bold>CA IX =</bold> Carbonic anhydraseIX; <bold>suPAR =</bold> Soluble urokinase plasminogen activator receptor</p></fn></table-wrap-foot></table-wrap>
</p><p>Spearman correlation analysis results of SCUBE-1, CAIX and suPAR in patient, control group and total sample is shown in <xref ref-type="table" rid="t3">Table-3</xref>. There was no correlation between biochemical parameters in patient, control group and total sample.</p><p>
<table-wrap id="t3" orientation="portrait" position="float"><label>Table 3</label><caption><title>Correlation analysis of biochemical parameters in patient, control group and total sample.</title></caption><table frame="hsides" rules="groups"><colgroup width="25%" span="1"><col span="1"/><col span="1"/><col span="1"/><col span="1"/></colgroup><thead><tr><th align="left" style="font-weight:normal" rowspan="1" colspan="1">Biochemical parameters</th><th style="font-weight:normal" rowspan="1" colspan="1">Group 1 Patient group</th><th style="font-weight:normal" rowspan="1" colspan="1">Group 2 Control group</th><th style="font-weight:normal" rowspan="1" colspan="1">Total sample</th></tr><tr><th align="left" colspan="4" style="font-weight:normal" rowspan="1">
<hr/>
</th></tr><tr><th style="font-weight:normal" rowspan="1" colspan="1">&#x000a0;</th><th style="font-weight:normal" rowspan="1" colspan="1">r - p</th><th style="font-weight:normal" rowspan="1" colspan="1">r - p</th><th style="font-weight:normal" rowspan="1" colspan="1">r - p</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">SCUBE-1 (ng/mL)- CAIX (pg/mL)</td><td align="center" rowspan="1" colspan="1">0.090 - 0.683</td><td align="center" rowspan="1" colspan="1">0.083 &#x02013; 0.692</td><td align="center" rowspan="1" colspan="1">0.112 - 0.450</td></tr><tr><td rowspan="1" colspan="1">SCUBE-1 - suPAR (ng/mL)</td><td align="center" rowspan="1" colspan="1">0.152 &#x02013; 0.487</td><td align="center" rowspan="1" colspan="1">0.173 &#x02013; 0.408</td><td align="center" rowspan="1" colspan="1">0.131 &#x02013; 0.375</td></tr><tr><td rowspan="1" colspan="1">CAIX (pg/mL) - suPAR (ng/mL)</td><td align="center" rowspan="1" colspan="1">0.058 &#x02013; 0.792</td><td align="center" rowspan="1" colspan="1">0.115 &#x02013; 0.585</td><td align="center" rowspan="1" colspan="1">0.153 &#x02013; 0.299</td></tr></tbody></table><table-wrap-foot><fn id="TFN3"><p>
<bold>SCUBE-1 =</bold> Signal peptide-CUB-EGF domain-containing protein 1; <bold>CA IX =</bold> Carbonic anhydraseIX; <bold>suPAR =</bold> Soluble urokinase plasminogen activator receptor</p></fn><fn id="TFN4"><p>
<bold>r =</bold> represents pearson coefficient of correlation; <bold>p =</bold> represents significance of coefficient of correlation</p></fn></table-wrap-foot></table-wrap>
</p></sec><sec sec-type="discussion"><title>DISCUSSION</title><p>Considerable advances have been made in recent years in the diagnosis of renal cancers, methods of treatment and prognosis. However, there is still a need for a marker with high sensitivity and specificity capable of use in the diagnosis and in determining prognosis of renal cancers.</p><p>Several studies have been performed with the aim of developing a biomarker with a high predictive value in renal tumors (<xref rid="B11" ref-type="bibr">11</xref>). CAIX is one biomarker that has been investigated for this purpose. CAIX was first tested as a predictive biomarker in a phase II study (SELECT trail), but the results were unsuccessful. CAIX was also investigated in mccRCC diagnosed patients using sorafenib, but no predictive or prognostic value was observed (<xref rid="B12" ref-type="bibr">12</xref>). Zhang et al. also concluded that CAIX is not an independent prognostic marker in patients diagnosed with CCRCC (<xref rid="B13" ref-type="bibr">13</xref>).</p><p>suPAR is a cell surface glycoprotein. Increased serum levels have been shown in several types of cancer. Elevated serum levels are closely correlated w&#x00131;th poor prognosis (<xref rid="B14" ref-type="bibr">14</xref>, <xref rid="B15" ref-type="bibr">15</xref>). In their study of patients with prostate cancer, Wach et al. revealed that high suPAR levels are a poor prognostic factor correlated with disease-specific survival (<xref rid="B7" ref-type="bibr">7</xref>). In a study of patients with gastrointestinal cancer, Zubkiewicz et al. suggested that suPAR is a significant prognostic marker in deciding on treatment in these cases (<xref rid="B8" ref-type="bibr">8</xref>).</p><p>SCUBE-1 is a member of the SCUBE gene family. Three different isoforms occur in mammals, SCUBE-1, -2 and -3. SCUBE-1 is a cell surface protein present in platelets and endothelial cells that is expressed and secreted in early embryogenesis (<xref rid="B9" ref-type="bibr">9</xref>). SCUBE-1 molecules are stored in alpha granules in inactive platelets. While thrombin is activated by platelets, SCUBE-1 is expressed on the platelet surface as a result of surface expression of the adhesion molecule P-selectin (<xref rid="B9" ref-type="bibr">9</xref>). It is released in the form of small, soluble particles incorporated into thrombus (<xref rid="B10" ref-type="bibr">10</xref>). In humans, it has robustly been shown in platelets and in fibrin-rich areas in organized thrombus (<xref rid="B16" ref-type="bibr">16</xref>).</p><p>SCUBE-1 has been investigated as a marker in non-cancer diseases (<xref rid="B17" ref-type="bibr">17</xref>-<xref rid="B21" ref-type="bibr">21</xref>). T&#x000fc;rkmen et al. described SCUBE-1 as a potential marker capable of use in the early stage of acute mesenteric ischemia, in the specific diagnosis of pulmonary embolism and in the early diagnosis of acute ischemic stroke (<xref rid="B17" ref-type="bibr">17</xref>-<xref rid="B19" ref-type="bibr">19</xref>). SCUBE-1 has also been described as a valuable biomarker in determining severity and prognosis of disease in patients with Crimean-Congo hemorrhagic fever (<xref rid="B20" ref-type="bibr">20</xref>). Ozkan et al. determined high SCUBE-1 levels in patients with hypertension and suggested that SCUBE-1 may be an early biomarker of potential thrombotic complications occurring in association with hypertension (<xref rid="B21" ref-type="bibr">21</xref>).</p><p>Various studies have investigated and shown a close association between cancers and thrombosis (<xref rid="B22" ref-type="bibr">22</xref>-<xref rid="B24" ref-type="bibr">24</xref>). Some tumors trigger the coagulation cascade and procoagulant substances and initiate the inflammatory process. Procoagulant substances are released from tumor cells with the inflammatory process (<xref rid="B25" ref-type="bibr">25</xref>). One in vitro study determined a decrease in SCUBE-1 concentrations with interleukin-1-&#x003b2; and TNF-&#x003b1; therapies, a finding implicating SCUBE-1 in the inflammatory process (<xref rid="B10" ref-type="bibr">10</xref>). Expression of SCUBE-1 transcripts in prostate cancer stromal cells was encountered in a series analysis of prostate mesenchymal cell gene expressions (<xref rid="B26" ref-type="bibr">26</xref>). Mentese et al. concluded that SCUBE-1 is a useful marker in determining recurrences that may occur after treatment in patients with stomach cancer (<xref rid="B27" ref-type="bibr">27</xref>). Topcu et al. reported that SCUBE-1 can be effective in determining the risk of thrombosis and in screening patients to receive anti-thrombotic therapy as a marker of hypercoagulability in patients with breast cancer (<xref rid="B28" ref-type="bibr">28</xref>). In the light of these studies, SCUBE-1 may be of significant value as a biomarker in renal cancer, with widespread angiogenesis and thrombosis. We also determined significantly higher SCUBE-1 values in patients with renal cell cancer. But there was no correlation between SCUBE-1 values and the pathological parameters like type, grade and stage. On the other hand, when we investigated the distribution of renal tumor stages in patients, there was only one patient with grade T3a renal tumor. Almost all of the patients were diagnosed and treated in early stages of the disease in our patient group. This could be a significant advantage for SCUBE-1 as an early cancer detection biomarker considering the distribution of the patients in the group.</p><p>The most important limitation of this study is the low number of patients with renal tumor and control cases enrolled. Further multicenter studies with larger patient series are now needed on this subject.</p></sec><sec sec-type="conclusions"><title>CONCLUSIONS</title><p>Research is continuing into different biomarkers in the diagnosis and prognosis and determination of response to treatment in renal tumors. In our study, SCUBE-1 levels were significantly elevated in cases of renal tumor. SCUBE-1 is a promising biomarker in the diagnosis and monitoring of patients with renal tumor, and further research with high number of cases is required.</p></sec></body><back><ack><title>ACKNOWLEDGEMENT</title><p>This study was supported by Karadeniz Technical University Scientific Research Project Administration Division Grant. (Project No: 9960)</p></ack><ref-list><title>REFERENCES</title><ref id="B1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Landis</surname><given-names>SH</given-names></name><name><surname>Murray</surname><given-names>T</given-names></name><name><surname>Bolden</surname><given-names>S</given-names></name><name><surname>Wingo</surname><given-names>PA</given-names></name></person-group><article-title>Cancer statistics, 1999</article-title><source>CA Cancer J Clin</source><year>1999</year><volume>49</volume><fpage>8</fpage><lpage>31</lpage><comment>1</comment><pub-id pub-id-type="pmid">10200775</pub-id></element-citation></ref><ref id="B2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lam</surname><given-names>JS</given-names></name><name><surname>Leppert</surname><given-names>JT</given-names></name><name><surname>Figlin</surname><given-names>RA</given-names></name><name><surname>Belldegrun</surname><given-names>AS</given-names></name></person-group><article-title>Role of molecular markers in the diagnosis and therapy of renal cell carcinoma</article-title><source>Urology</source><year>2005</year><volume>66</volume><issue>5 Suppl</issue><fpage>1</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">16194700</pub-id></element-citation></ref><ref id="B3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zatovicova</surname><given-names>M</given-names></name><name><surname>Sedlakova</surname><given-names>O</given-names></name><name><surname>Svastova</surname><given-names>E</given-names></name><name><surname>Ohradanova</surname><given-names>A</given-names></name><name><surname>Ciampor</surname><given-names>F</given-names></name><name><surname>Arribas</surname><given-names>J</given-names></name><etal>et al</etal></person-group><article-title>Ectodomain shedding of the hypoxia-induced carbonic anhydrase IX is a metalloprotease-dependent process regulated by TACE/ADAM17</article-title><source>Br J Cancer</source><year>2005</year><volume>93</volume><fpage>1267</fpage><lpage>1276</lpage><pub-id pub-id-type="pmid">16278664</pub-id></element-citation></ref><ref id="B4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bui</surname><given-names>MH</given-names></name><name><surname>Seligson</surname><given-names>D</given-names></name><name><surname>Han</surname><given-names>KR</given-names></name><name><surname>Pantuck</surname><given-names>AJ</given-names></name><name><surname>Dorey</surname><given-names>FJ</given-names></name><name><surname>Huang</surname><given-names>Y</given-names></name><etal>et al</etal></person-group><article-title>Carbonic anhydrase IX is an independent predictor of survival in advanced renal clear cell carcinoma: implications for prognosis and therapy</article-title><source>Clin Cancer Res</source><year>2003</year><volume>9</volume><fpage>802</fpage><lpage>811</lpage><pub-id pub-id-type="pmid">12576453</pub-id></element-citation></ref><ref id="B5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thun&#x000f8;</surname><given-names>M</given-names></name><name><surname>Macho</surname><given-names>B</given-names></name><name><surname>Eugen-Olsen</surname><given-names>J</given-names></name></person-group><article-title>suPAR: the molecular crystal ball</article-title><source>Dis Markers</source><year>2009</year><volume>27</volume><fpage>157</fpage><lpage>172</lpage><pub-id pub-id-type="pmid">19893210</pub-id></element-citation></ref><ref id="B6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eugen-Olsen</surname><given-names>J</given-names></name><name><surname>Andersen</surname><given-names>O</given-names></name><name><surname>Linneberg</surname><given-names>A</given-names></name><name><surname>Ladelund</surname><given-names>S</given-names></name><name><surname>Hansen</surname><given-names>TW</given-names></name><name><surname>Langkilde</surname><given-names>A</given-names></name><etal>et al</etal></person-group><article-title>Circulating soluble urokinase plasminogen activator receptor predicts cancer, cardiovascular disease, diabetes and mortality in the general population</article-title><source>J Intern Med</source><year>2010</year><volume>268</volume><fpage>296</fpage><lpage>308</lpage><pub-id pub-id-type="pmid">20561148</pub-id></element-citation></ref><ref id="B7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wach</surname><given-names>S</given-names></name><name><surname>Al-Janabi</surname><given-names>O</given-names></name><name><surname>Weigelt</surname><given-names>K</given-names></name><name><surname>Fischer</surname><given-names>K</given-names></name><name><surname>Greither</surname><given-names>T</given-names></name><name><surname>Marcou</surname><given-names>M</given-names></name><etal>et al</etal></person-group><article-title>The combined serum levels of miR-375 and urokinase plasminogen activator receptor are suggested as diagnostic and prognostic biomarkers in prostate cancer</article-title><source>Int J Cancer</source><year>2015</year><volume>137</volume><fpage>1406</fpage><lpage>1416</lpage><pub-id pub-id-type="pmid">25754273</pub-id></element-citation></ref><ref id="B8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Usnarska-Zubkiewicz</surname><given-names>L</given-names></name><name><surname>Struty&#x00144;ska-Karpi&#x00144;ska</surname><given-names>M</given-names></name><name><surname>Zubkiewicz-Kucharska</surname><given-names>A</given-names></name><name><surname>Zar&#x00119;bski</surname><given-names>P</given-names></name><name><surname>Grabowski</surname><given-names>K</given-names></name></person-group><article-title>Soluble urokinase-type plasminogen activator receptor and ferritin concentration in patients with advanced alimentary tract carcinoma. Relationship to localization, surgical treatment and the stage of the disease--preliminary report</article-title><source>Adv Clin Exp Med</source><year>2014</year><volume>23</volume><fpage>959</fpage><lpage>967</lpage><pub-id pub-id-type="pmid">25618124</pub-id></element-citation></ref><ref id="B9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tu</surname><given-names>CF</given-names></name><name><surname>Yan</surname><given-names>YT</given-names></name><name><surname>Wu</surname><given-names>SY</given-names></name><name><surname>Djoko</surname><given-names>B</given-names></name><name><surname>Tsai</surname><given-names>MT</given-names></name><name><surname>Cheng</surname><given-names>CJ</given-names></name><etal>et al</etal></person-group><article-title>Domain and functional analysis of a novel platelet-endothelial cell surface protein, SCUBE1</article-title><source>J Biol Chem</source><year>2008</year><volume>283</volume><fpage>12478</fpage><lpage>12488</lpage><pub-id pub-id-type="pmid">18303018</pub-id></element-citation></ref><ref id="B10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>RB</given-names></name><name><surname>Ng</surname><given-names>CK</given-names></name><name><surname>Wasserman</surname><given-names>SM</given-names></name><name><surname>Colman</surname><given-names>SD</given-names></name><name><surname>Shenoy</surname><given-names>S</given-names></name><name><surname>Mehraban</surname><given-names>F</given-names></name><etal>et al</etal></person-group><article-title>Identification of a novel family of cell-surface proteins expressed in human vascular endothelium</article-title><source>J Biol Chem</source><year>2002</year><volume>277</volume><fpage>46364</fpage><lpage>46373</lpage><pub-id pub-id-type="pmid">12270931</pub-id></element-citation></ref><ref id="B11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Atkins</surname><given-names>MB</given-names></name></person-group><article-title>Treatment selection for patients with metastatic renal cell carcinoma: identification of features favoring upfront IL-2-based immunotherapy</article-title><source>Med Oncol</source><year>2009</year><volume>26</volume><issue>Suppl 1</issue><fpage>18</fpage><lpage>22</lpage><pub-id pub-id-type="pmid">19165638</pub-id></element-citation></ref><ref id="B12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Choueiri</surname><given-names>TK</given-names></name><name><surname>Cheng</surname><given-names>S</given-names></name><name><surname>Qu</surname><given-names>AQ</given-names></name><name><surname>Pastorek</surname><given-names>J</given-names></name><name><surname>Atkins</surname><given-names>MB</given-names></name><name><surname>Signoretti</surname><given-names>S</given-names></name></person-group><article-title>Carbonic anhydrase IX as a potential biomarker of efficacy in metastatic clear-cell renal cell carcinoma patients receiving sorafenib or placebo: analysis from the treatment approaches in renal cancer global evaluation trial (TARGET)</article-title><source>Urol Oncol</source><year>2013</year><volume>31</volume><fpage>1788</fpage><lpage>1793</lpage><pub-id pub-id-type="pmid">23141780</pub-id></element-citation></ref><ref id="B13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>BY</given-names></name><name><surname>Thompson</surname><given-names>RH</given-names></name><name><surname>Lohse</surname><given-names>CM</given-names></name><name><surname>Dronca</surname><given-names>RS</given-names></name><name><surname>Cheville</surname><given-names>JC</given-names></name><name><surname>Kwon</surname><given-names>ED</given-names></name><etal>et al</etal></person-group><article-title>Carbonic anhydrase IX (CAIX) is not an independent predictor of outcome in patients with clear cell renal cell carcinoma (ccRCC) after long-term follow-up</article-title><source>BJU Int</source><year>2013</year><volume>111</volume><fpage>1046</fpage><lpage>1053</lpage><pub-id pub-id-type="pmid">23551810</pub-id></element-citation></ref><ref id="B14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Blasi</surname><given-names>F</given-names></name></person-group><article-title>The urokinase receptor. A cell surface, regulated chemokine</article-title><source>APMIS</source><year>1999</year><volume>107</volume><fpage>96</fpage><lpage>101</lpage><pub-id pub-id-type="pmid">10190285</pub-id></element-citation></ref><ref id="B15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mekkawy</surname><given-names>AH</given-names></name><name><surname>Pourgholami</surname><given-names>MH</given-names></name><name><surname>Morris</surname><given-names>DL</given-names></name></person-group><article-title>Involvement of urokinase-type plasminogen activator system in cancer: an overview</article-title><source>Med Res Rev</source><year>2014</year><volume>34</volume><fpage>918</fpage><lpage>956</lpage><pub-id pub-id-type="pmid">24549574</pub-id></element-citation></ref><ref id="B16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grimmond</surname><given-names>S</given-names></name><name><surname>Larder</surname><given-names>R</given-names></name><name><surname>Van Hateren</surname><given-names>N</given-names></name><name><surname>Siggers</surname><given-names>P</given-names></name><name><surname>Hulsebos</surname><given-names>TJ</given-names></name><name><surname>Arkell</surname><given-names>R</given-names></name><etal>et al</etal></person-group><article-title>Cloning, mapping, and expression analysis of a gene encoding a novel mammalian EGF-related protein (SCUBE1)</article-title><source>Genomics</source><year>2000</year><volume>70</volume><fpage>74</fpage><lpage>81</lpage><pub-id pub-id-type="pmid">11087664</pub-id></element-citation></ref><ref id="B17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Turkmen</surname><given-names>S</given-names></name><name><surname>Mentese</surname><given-names>S</given-names></name><name><surname>Mentese</surname><given-names>A</given-names></name><name><surname>Sumer</surname><given-names>AU</given-names></name><name><surname>Saglam</surname><given-names>K</given-names></name><name><surname>Yulug</surname><given-names>E</given-names></name><etal>et al</etal></person-group><article-title>The value of signal peptide-CUB-EGF domain-containing protein 1 and oxidative stress parameters in the diagnosis of acute mesenteric ischemia</article-title><source>Acad Emerg Med</source><year>2013</year><volume>20</volume><fpage>257</fpage><lpage>264</lpage><pub-id pub-id-type="pmid">23517257</pub-id></element-citation></ref><ref id="B18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Turkmen</surname><given-names>S</given-names></name><name><surname>Sahin</surname><given-names>A</given-names></name><name><surname>Gunaydin</surname><given-names>M</given-names></name><name><surname>Sahin</surname><given-names>S</given-names></name><name><surname>Mentese</surname><given-names>A</given-names></name><name><surname>Turedi</surname><given-names>S</given-names></name><etal>et al</etal></person-group><article-title>The value of signal peptide-CUB-EGF domain-containing protein-1 (SCUBE1) in the diagnosis of pulmonary embolism: a preliminary study</article-title><source>Acad Emerg Med</source><year>2015</year><volume>22</volume><fpage>922</fpage><lpage>926</lpage><pub-id pub-id-type="pmid">26202675</pub-id></element-citation></ref><ref id="B19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Turkmen</surname><given-names>S</given-names></name><name><surname>Eryigit</surname><given-names>U</given-names></name><name><surname>Karaca</surname><given-names>Y</given-names></name><name><surname>Mentese</surname><given-names>A</given-names></name><name><surname>Sumer</surname><given-names>UA</given-names></name><name><surname>Yulug</surname><given-names>E</given-names></name><etal>et al</etal></person-group><article-title>Diagnostic value of plasma signal peptide-Cub-Egf domain-containing protein-1 (SCUBE-1) in an experimental model of acute ischemic stroke</article-title><source>Am J Emerg Med</source><year>2015</year><volume>33</volume><fpage>262</fpage><lpage>265</lpage><pub-id pub-id-type="pmid">25541225</pub-id></element-citation></ref><ref id="B20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mente&#x0015f;e</surname><given-names>A</given-names></name><name><surname>Yilmaz</surname><given-names>G</given-names></name><name><surname>S&#x000fc;mer</surname><given-names>A</given-names></name><name><surname>Arslan</surname><given-names>M</given-names></name><name><surname>Karahan</surname><given-names>SC</given-names></name><name><surname>K&#x000f6;ksal</surname><given-names>I</given-names></name></person-group><article-title>The diagnostic and prognostic significance of SCUBE1 levels in Crimean-Congo hemorrhagic fever</article-title><source>Int J Infect Dis</source><year>2013</year><volume>17</volume><elocation-id>e1042-5</elocation-id><pub-id pub-id-type="pmid">23632301</pub-id></element-citation></ref><ref id="B21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>&#x000d6;zkan</surname><given-names>G</given-names></name><name><surname>Ulusoy</surname><given-names>S</given-names></name><name><surname>Mente&#x0015f;e</surname><given-names>A</given-names></name><name><surname>Karahan</surname><given-names>SC</given-names></name><name><surname>Cansiz</surname><given-names>M</given-names></name></person-group><article-title>New marker of platelet activation, SCUBE1, is elevated in hypertensive patients</article-title><source>Am J Hypertens</source><year>2013</year><volume>26</volume><fpage>748</fpage><lpage>753</lpage><pub-id pub-id-type="pmid">23443724</pub-id></element-citation></ref><ref id="B22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McMahon</surname><given-names>B</given-names></name><name><surname>Kwaan</surname><given-names>HC</given-names></name></person-group><article-title>The plasminogen activator system and cancer</article-title><source>Pathophysiol Haemost Thromb</source><year>2008</year><volume>36</volume><fpage>184</fpage><lpage>194</lpage><pub-id pub-id-type="pmid">19176991</pub-id></element-citation></ref><ref id="B23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kwaan</surname><given-names>HC</given-names></name><name><surname>McMahon</surname><given-names>B</given-names></name></person-group><article-title>The role of plasminogen-plasmin system in cancer</article-title><source>Cancer Treat Res</source><year>2009</year><volume>148</volume><fpage>43</fpage><lpage>66</lpage><pub-id pub-id-type="pmid">19377918</pub-id></element-citation></ref><ref id="B24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Andreasen</surname><given-names>PA</given-names></name><name><surname>Egelund</surname><given-names>R</given-names></name><name><surname>Petersen</surname><given-names>HH</given-names></name></person-group><article-title>The plasminogen activation system in tumor growth, invasion, and metastasis</article-title><source>Cell Mol Life Sci</source><year>2000</year><volume>57</volume><fpage>25</fpage><lpage>40</lpage><pub-id pub-id-type="pmid">10949579</pub-id></element-citation></ref><ref id="B25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>De Cicco</surname><given-names>M</given-names></name></person-group><article-title>The prothrombotic state in cancer: pathogenic mechanisms</article-title><source>Crit Ver Oncol Hematol</source><year>2004</year><volume>50</volume><fpage>187</fpage><lpage>196</lpage></element-citation></ref><ref id="B26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vanpoucke</surname><given-names>G</given-names></name><name><surname>Orr</surname><given-names>B</given-names></name><name><surname>Grace</surname><given-names>OC</given-names></name><name><surname>Chan</surname><given-names>R</given-names></name><name><surname>Ashley</surname><given-names>GR</given-names></name><name><surname>Williams</surname><given-names>K</given-names></name><etal>et al</etal></person-group><article-title>Transcriptional profiling of inductive mesenchyme to identify molecules involved in prostate development and disease</article-title><source>Genome Biol</source><year>2007</year><volume>8</volume><size units="pages">R213</size></element-citation></ref><ref id="B27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mentese</surname><given-names>A</given-names></name><name><surname>Fidan</surname><given-names>E</given-names></name><name><surname>Sumer</surname><given-names>AU</given-names></name><name><surname>Karahan</surname><given-names>SC</given-names></name><name><surname>Sonmez</surname><given-names>M</given-names></name><name><surname>Altay</surname><given-names>DU</given-names></name><etal>et al</etal></person-group><article-title>Is SCUBE 1 a new biomarker for gastric cancer?</article-title><source>Cancer Biomark</source><year>2012</year><volume>11</volume><fpage>191</fpage><lpage>195</lpage><pub-id pub-id-type="pmid">23220851</pub-id></element-citation></ref><ref id="B28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Topcu</surname><given-names>TO</given-names></name><name><surname>Kavgaci</surname><given-names>H</given-names></name><name><surname>Ozdemir</surname><given-names>F</given-names></name><name><surname>Aksoy</surname><given-names>A</given-names></name><name><surname>Erdem</surname><given-names>D</given-names></name><name><surname>Mentese</surname><given-names>A</given-names></name><etal>et al</etal></person-group><article-title>Elevated Serum Levels of SCUBE1, a Marker for Coagulation, in Patients with Breast Cancer</article-title><source>Tohoku J Exp Med</source><year>2015</year><volume>237</volume><fpage>127</fpage><lpage>132</lpage><pub-id pub-id-type="pmid">26438214</pub-id></element-citation></ref></ref-list></back></article>